The study found that patients were who giving a combination of the anti-inflammatory drug baricitinib and the antiviral drug remdesivir while receiving high flow oxygen or noninvasive ventilation had a recovery time of 10 days, compared with 18 days for patients receiving only remdesivir.
Read more: https://cbsloc.al/2YlCRNe